Status:
COMPLETED
Thrombospondin-4 Levels and Peripheral Arterial Disease in Hemodialysis Patients
Lead Sponsor:
Tungs' Taichung Metroharbour Hospital
Conditions:
Peripheral Arterial Disease
Eligibility:
All Genders
20+ years
Brief Summary
Background: Peripheral arterial disease (PAD) a condition characterized by atherosclerotic occlusive disease of the lower extremities is commonly observed in patients with chronic kidney disease (CKD...
Detailed Description
Study Population and Data Source This is a cross-sectional, single-center study which will be conducted in the Dialysis Center of Tungs' Taichung MetroHarbor Hospital (TTMHH) in the coastal region of ...
Eligibility Criteria
Inclusion
- A cohort of aged 20 or over, who have been on HD for at least 3 months prior to enrollment (Dec 1, 2021) will be included.
Exclusion
- (1) baseline ABI values \> 1.3 , (2) symptomatic PAD , (3) decompensated cirrhosis , (4) neoplastic diseases , (5) incomplete data, (6) receiving hemodialysis \< 3 months and active infection.
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
280 Patients enrolled
Trial Details
Trial ID
NCT04735562
Start Date
April 1 2021
End Date
December 31 2021
Last Update
February 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tungs' Taichung MetroHarbour Hospital
Taichung, Taiwan